Longevity Health Surges 60% After Merger With THPlasma

Longevity Health Holdings Inc. announced a definitive merger agreement with True Health Inc., operating under the THPlasma brand, in an all-stock transaction valued at $59 million plus $20 million in earnouts. This merger, expected to close in the fourth quarter of 2025, will expand Longevity's footprint in the plasma collection industry, addressing the U.S. plasma supply shortfall despite it supplying over 60% of the world's plasma. THPlasma anticipates significant growth, with revenues projected to increase from $10 million in FY2025 to $32 million in FY2026, alongside an expansion from two to five plasma collection centers. Post-merger, THPlasma's CEO George Chi will serve as Co-Chairman and CEO of the combined company, while Longevity's Rajiv Shukla will be Executive Chairman. The merger follows Longevity's recent acquisitions of Carmell Therapeutics and Elevai Skincare, and coincides with the termination of its previously planned transaction with 20/20 BioLabs. Investor confidence was reflected in a nearly 60% surge in Longevity's stock price during after-hours trading following the announcement.